Biologics Market is Anticipated to Reach Around US$ 535.5 Billion By 2028 | Growth Rate (CAGR) of 8.1%

According to IMARC Group latest report titled "Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028", offers a comprehensive analysis of the industry, which comprises insights on biologics market. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global biologics market size reached US$ 321.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 535.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.1% during 2023-2028.

Biologics are a type of medical product derived from living organisms or their components, such as proteins or molecules. They are utilized in various medical treatments, including cancer, autoimmune diseases, and infectious diseases. They are produced using numerous methods, such as recombinant DNA technology, which involves inserting foreign genetic material into a host organism or using living organisms to generate molecules with desired properties. They are composed of proteins or polysaccharides, which are derived from living cells or tissues. They also include small molecules, such as hormones, enzymes, or antibodies. They are administered through injection, inhalation, or infusion and are used to treat several conditions. They replace, supplement, or enhance the body's natural defenses against disease-causing agents. They target specific cells or tissues, making them helpful in treating conditions that require more precise targeting, such as autoimmune diseases. Moreover, they are often combined with other treatments, such as chemotherapy or radiation therapy, to achieve better outcomes.

Get a Free Sample Copy of this Report: https://www.imarcgroup.com/biologics-market/requestsample

Market Trends:

The escalating demand for early diagnosis across the globe majorly drives the global market. This can be supported by the rising prevalence of chronic diseases, including cancer, diabetes, arthritis, Crohn's disease, multiple sclerosis, and cardiovascular diseases. Along with this, biologics are effective in treating a wide range of conditions as well as offering potential therapies for rare and orphan diseases, which is significantly supporting the market. In addition, governments and industries are investing heavily in biologics research and development (R&D) activities and are introducing policies that support the development and commercialization of biologics, is acting as another growth-inducing factor. Apart from this, the rising demand for personalized medicine due to its greater specificity than traditional small-molecule drugs is also positively influencing the overall market. Furthermore, continuous advancements in biotechnology, such as gene editing and gene therapy, offering complex and sophisticated biologics, are creating a positive market outlook.

View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biologics-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi

Biologics Market Segmentation:

Our report has categorized the market based on region, source, product, disease and manufacturing.

Breakup by Source:
• Microbial
• Mammalian
• Others

Breakup by Product:
• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense, RNAi and Molecular Therapy
• Others

Breakup by Disease:
• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

Breakup by Manufacturing:
• Outsourced
• In-House

Breakup by Region:
• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:
• Market Performance (2017-2022)
• Market Outlook (2023-2028)
• Porter's Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

Browse Other Reports of IMARC Group:

Stoma/Ostomy Care Market: https://www.imarcgroup.com/stoma-ostomy-care-market

T-cell Therapy Market: https://www.imarcgroup.com/t-cell-therapy-market

Healthcare Payer Services Market: https://www.imarcgroup.com/healthcare-payer-services-market

Neurostimulation Devices Market: https://www.imarcgroup.com/neurostimulation-devices-market

Biopharmaceutical Market: https://www.imarcgroup.com/biotechnology-industry

Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.